干酵母发酵液选择性地调节肠腔和肠粘膜微生物群,并防止炎症,这是一个综合的体外研究方法。

PubMed ID
发表日期 2013年Oct月

原始出处 农业与食品化学杂志
Journal of agricultural and food chemistry
作者 Possemiers  Sam  Pinheiro  Iris  Verhelst  An  Van den Abbeele  Pieter  Maignien  Lois  Laukens  Debby  Reeves  Stuart G  Robinson  Larry E  Raas  Thomas  Schneider  Yves-Jacques  Van de Wiele  Tom  Marzorati  Massimo 

文献标题 干酵母发酵液选择性地调节肠腔和肠粘膜微生物群,并防止炎症,这是一个综合的体外研究方法。
A dried yeast fermentate selectively modulates both the luminal and mucosal gut microbiota and protects against inflammation, as studied in an integrated in vitro approach.

文献摘要

EpiCor来源于酿酒酵母,在人体临床试验和体外实验中已被证明具有免疫调节特性。然而,其通过肠道进行免疫保护的潜在机制仍不清楚。因此,本研究的目的是利用一个完整的体外方法来评估肠内菌群对EpiCor的代谢、对肠道菌群的调节作用以及对人源性细胞系的抗炎活性。使用SHIME模型,结合黏液粘附试验,已经表明低剂量的EpiCor对管腔和粘膜相关微生物群具有类似益生元的调节作用。这些变化包括一般群落结构的逐渐变化、潜在病原体的减少、乳酸菌数量的增加和双歧杆菌的质量调节。此外,通过SHIME与Caco-2细胞和Caco-2/THP1共培养,在治疗期结束时发现促炎细胞因子显著减少。


EpiCor, derived from Saccharomyces cerevisiae, has been shown to have immunomodulating properties in human clinical trials and in vitro. However, the underlying mechanisms behind its immune protection via the gut remain largely unknown. Therefore, the aim of this study was to use an integrated in vitro approach to evaluate the metabolism of EpiCor by the intestinal microflora, its modulating effect on the gut microbiota, and its anti-inflammatory activity on human-derived cell lines. Using the SHIME model, in combination with a mucus adhesion assay, has shown that low doses of EpiCor have a prebiotic-like modulatory effect on the luminal- and mucosa-associated microbiota. These include gradual changes in general community structure, reduction of potential pathogens, quantitative increase in lactobacilli, and qualitative modulation of bifidobacteria. Moreover, by combination of the SHIME with Caco-2 cells and Caco-2/THP1 cocultures, a significant decrease in pro-inflammatory cytokines was observed at the end of the treatment period.


获取全文 10.1021/jf402137r